Pelthos Therapeutics PTHS
NYSE PTHS
$8.97 -0.40 (-4.27%)
As of: Nov 10, 2026 · 3:59 PM EST

Pelthos Therapeutics (PTHS) Convertible Debt (2025 - 2026)

Updated

Pelthos Therapeutics (PTHS) reported Convertible Debt of $43.32 million for Q2 2026, up 10.7% from the prior quarter.

Analysis

Pelthos Therapeutics (PTHS) Convertible Debt (2025 - 2026) Analysis & Trends

At the end of FY2025, Pelthos Therapeutics posted Convertible Debt of $31.44 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn
10 Pelthos Therapeutics 32.83 Mn -55.57 Mn 11.99 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 43.32 Mn
Mar 31, 2026 39.12 Mn
Dec 31, 2025 31.44 Mn
API Access

Pelthos Therapeutics Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=PTHS&period=max&api_key=YOUR_API_KEY